CN1179723C - Application of geldanamycin in preparation of medicine for curing SARS - Google Patents
Application of geldanamycin in preparation of medicine for curing SARS Download PDFInfo
- Publication number
- CN1179723C CN1179723C CNB031465919A CN03146591A CN1179723C CN 1179723 C CN1179723 C CN 1179723C CN B031465919 A CNB031465919 A CN B031465919A CN 03146591 A CN03146591 A CN 03146591A CN 1179723 C CN1179723 C CN 1179723C
- Authority
- CN
- China
- Prior art keywords
- geldanamycin
- sars
- cell
- medicine
- vero
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to an application of geldanamycin on preparing medicine for treating severe acute respiratory syndrome. The inhibition test of geldanamycin to SARS coronavirus with the cytopathy method indicates that geldanamycin has obvious inhibiting effect on the duplication of SARS coronavirus, IC50 is from 0.34 to 1.57 mumol/L, and the therapeutic index is from 19 to 88.
Description
Technical field
The present invention relates to the application of geldanamycin (Geldanamycin) in preparation treatment SARS (Severe Acute Respiratory Syndrome) (SARS) medicine.
Background technology
Geldanamycin is to have a broad-spectrum disease resistance toxic action secondary metabolite of (comprising DNA and RNA viruses) by what Inst. of Medicinal Biological Technology, Chinese Academy of Medical Sciences's isolating geldanamycin in the soil of Luojia Mountain, Wuhan, Hubei Province area produced separation and purification in the fermentation liquid of bacterium (actinomycetes C-3559).
The first half of the year in 2003, a country has met with the attack of paroxysmal SARS (Severe Acute Respiratory Syndrome) (severe acute respiratory syndrome, english abbreviation SARS) (hereinafter to be referred as SARS) surplus the China and the world 20, and this disease is by due to the sars coronavirus, infectiousness is extremely strong, infect soon, incubation period is short, only has 2~14 days, number of the infected is many, the death rate of the onset height, very harmful, and still do not have the specially good effect antiviral drugs.
Summary of the invention
The purpose of this invention is to provide the application of a kind of geldanamycin in preparation treatment SARS (Severe Acute Respiratory Syndrome) medicine.
Geldanamycin is to have a broad-spectrum disease resistance toxic action secondary metabolite of (comprising DNA and RNA viruses) by what Inst. of Medicinal Biological Technology, Chinese Academy of Medical Sciences's isolating geldanamycin in the soil of Luojia Mountain, Wuhan, Hubei Province area produced separation and purification in the fermentation liquid of bacterium (actinomycetes C-3559).
Actinomycetes C-3559 belongs to the suction monoid of streptomycete, pitch-dark streptomycete, S.atrolaccus Ye n 1957.Its morphological characteristic comprises: the base silk does not rupture, and has only the gas silk to form spore chain, and fibrillae of spores is tight spiral type, do not form sclerotium and conidium device, spore surface is smooth, and cultural characteristic comprises: after the spore maturation, the fibrillae of spores self-dissolving makes the bacterium colony surface form the wet speckle (suction phenomenon) of black viscosity.
Shellfish Nat culture medium | Grape sugar asparagine culture medium | ||||
The gas silk | The base silk | Pigment | The gas silk | The base silk | Pigment |
Greyish black | The gold leaf Huang | Trace gold leaf Huang | Greyish black | Milky white | Do not have |
Physiological feature comprises: 1. utilization of carbon source: at the culture medium well-grown of carbon sources such as glucose, fructose, sucrose, xylose, mannose, arabinose, rhamnose, maltose and inositol.2. other physiological feature: cellulose does not utilize, and milk peptonizes, the nitrate reduction feminine gender.The cell wall chemical feature comprises: contain LL-DAP and belong to cell wall I type, sugared type C does not contain characteristic sugar.
The extraction of geldanamycin, separation method
1. X5 macroporous adsorptive resins on the filtering fermentation liquor rear filtrate, absorption finish after water dashes, and wash live part with 80% acetone, and removing acetone, yellow mercury oxide is arranged is the geldanamycin crude product.
2. above-mentioned geldanamycin crude product, reuse macroporous absorption post carries out the chromatography second time, washes live part with 80% acetone, and purity is placed on and separates out yellow acicular crystal in the refrigerator more than 90%, is purity and reaches geldanamycin more than 95%.Carry out secondary recrystallization again, purity can reach the geldanamycin more than 98%.Extraction recovery can reach 30%~35%.
To adopting the single active component of said method extraction separation in the fermentation liquid of actinomycetes C-3559, the i.e. mensuration of C-3559 active constituent physicochemical property and discriminating
Active constituent is carried out stability, fusing point, dissolubility, elementary analysis, UV, IR, MS reach
1HNMR reaches
18The mensuration of wave spectrums such as CNMR and DEPT spectrum, and carried out the retrieval of documents and materials, find that it is identical with the geldanamycin of benzene Ansamycin apoplexy due to endogenous wind.
Both property lists are compared to following table:
Character | C-3559 | Geldanamycin |
Proterties solubility stability fusing point elementary analysis weight molecule formula UV (nm) IR by1NHMR, 18CNMR and DEPT spectrum | Yellow acicular crystal is soluble in chloroform, organic solvents such as dichloromethane, be dissolved in acetone slightly, methanol etc., it is stable to be slightly soluble in the water dry product, and solution is to warm, acid, alkali, 253 ℃ of-256 ℃ of C of photo-labile 62.12H 7.08N 4.93(025.87) 560(FABM) C 29H 40N 2O 9304 256 (methyl alcohol) KBr sheet, 3,510 3,446 3,350 3,315 1,734 1,705 1,675 1,655 1,615 1,595 1,510 1108 1057CM-11. 18The CNMR spectrum is measured as 29 carbon 2. and finds out that by DEPT 2 CH of 11-CH of 9 quaternary carbons are arranged 27 CH 3 | Yellow acicular crystal is soluble in chloroform, dichloroethanes etc., be dissolved in acetone slightly, ethyl acetate etc., it is stable to be slightly soluble in the water dry product, and solution is to warm, unstable 252 ℃ of soda acid--255 ℃ of value of calculation: C 61.69H 7.16N 5.15(025.65) measured value: C 62.13H 7.26N 5.0(025.65) 560 C 29H 40N 2O 9304 255 (methyl alcohol) nujol mull, 3,510 3,445 3,350 3,315 1,734 1,700 1,676 1,655 1,635 1,608 1,590 1,510 1108 1057CM-12 CH of 11-CH of 9 quaternary carbons of 29 carbon are arranged 27 CH 3 |
According to above-mentioned data, we infer that active component C-3559 should have the structure identical with geldanamycin.
With the sick epidemic period of in February, 2003 Beijing SARS by Viral Laboratory, Microbiology and Epidemic Disease Inst., Academy of Military-Medical Sciences (C Micro biological Tests research center from isolating viral BJ 01 strain of Beijing patient's lung tissue and responsive Vero-E thereof
6Cell, the regulation by extracorporeal antivirus effect test of pesticide effectiveness part in " new drug (Western medicine) preclinical study guideline " detects geldanamycin (hereinafter to be referred as C-3559) to Vero-E
6The toxicity of cell and at Vero-E
6The interior inhibition effect of cell to sars coronavirus.Repeated experiments shows: geldanamycin (C-3559) is at Vero-E
6The IC that suppresses sars coronavirus in the cell
50Be 0.34~1.57umol/L, the IC of positive control drug ribavirin
50Be 52.0ug/ml.Illustrate that geldanamycin (C-3559) can obviously suppress sars coronavirus and duplicate.
Be the external SARS coronary virus resistant drug effect of the medicine examining report that carries out at geldanamycin of the present invention below.
One. test objective: detect the effect of the external SARS coronary virus resistant of C-3559.Detect unit: Viral Laboratory, Microbiology and Epidemic Disease Inst., Academy of Military-Medical Sciences (C Micro biological Tests research center.
Two. material
1. be subjected to reagent:
C-3559 (purity>98%) is provided by Inst. of Medicinal Biological Technology, Chinese Academy of Medical Sciences.
2. positive control medicine:
Ribavirin (virazole) injection, 0.1g/ml, Shandong XinHua Pharmacy stock Co., Ltd produces, authentication code: H19993063, lot number: 02100020.Clinical application: be used for viral pneumonia and bronchitis that respiratory syncytial virus causes.Clinical Coming-of-Age Day, consumption was a 0.5g, 2 times on the one.
3. cell:
The Vero-E6 cell, preserve in this ventricular cell storehouse.With the DMEM culture fluid that contains 10% hyclone, at 37 ℃ of 5%CO
2Incubator was cultivated 2-3 days, went down to posterity once.
4. Strain:
Sars coronavirus, in February, 2003 the sars coronavirus epidemic period, by the isolated viral BJ01 strain from the patient's lung tissue of Beijing of this chamber, the 5th generation.
5. reagent:
DMEM culture medium and hyclone, Gibco BRL company product, lot number is respectively 31600-026 and 16000-36.
6. instrument:
96 porocyte culture plates, Corning company.Biological inverted microscope XDS-1B type, the optical instrument factory, Chongqing.
Three. method and result
(1) compound method of medicine
Be subjected to reagent: C-3559, yellow powder is mixed with the 10mmol/L mother solution with DMSO, 0.22 μ m disposable aspiration needle formula filter filtration sterilization, 4 ℃ of preservations.The medicinal pure water of positive control is mixed with the 10mg/ml mother solution.Be mixed with desired concn with cell growth medium during use.
2.C-3559 toxic action to the Vero-E6 cell
Every milliliter 30~400,000 Vero-E6 cell inoculation % porocyte culture plates, every hole 0.1ml puts 37 ℃ of 5%CO
2Incubator is cultivated 24h, the test medicine that adds variable concentrations, test medicine doubling dilution is 80~5 μ mol/L, each concentration 4 hole, every hole 0.1ml establishes no drug cell matched group simultaneously, cultivated 5 days, with observation of cell metamorphosis (CPE) is index, and be inverted observed and recorded CPE under the apparent mirror every day, and Gestalt is changed to 4; 75% is 3; 50% is 2; 25% is 1; No form is changed to 0.According to the REED-MUENCH method, calculate the maximal non-toxic concentration (TD of this medicine to the Vero-E6 cell
0) be 20 μ mol/L and median toxic concentration (TD
50) be 30 μ mol/L.The TD of positive control drug ribavirin
0And TD
50For greater than 6000 μ g/ml.Test repeats secondary, unanimity as a result.
3.SARS coronavirus toxicity test (micromethod)
Sars coronavirus BJ01 strain the 5th generation virus liquid is kept the continuous 10 times of dilutions of liquid with DMEM: 10
-1~10
-10The viral liquid of variable concentrations of dilution is inoculated in the Vero-E6 cell 96 well culture plate holes that grow up to monolayer, each concentration 4 hole, every hole 0.1ml establishes the normal cell contrast simultaneously, puts 37 ℃ of 5%CO
2Cultivate in the incubator, observed CPE continuously 5~7 days, the record result.Calculate 50 3nfective dose (TCID according to the REED-MUENCH method
50).
4.C-3559 inhibition test (cellular morphology method of changing) to sars coronavirus
With every milliliter 30~400,000 Vero-E6 cell inoculations to 96 well culture plates, 37 ℃ of 5%CO
2Cultivate 24h in the incubator, discard growth-promoting media, with sars coronavirus BJ01 strain the 5th generation virus liquid, keeping the liquid dilution with DMEM is 10~100 TCID
50/ 0.1ml, every hole 0.1ml inoculation Vero-E6 cell adsorbed 2 hours, discarded viral liquid.Add the variable concentrations medicinal liquid, test medicine doubling dilution is 20~0.3 μ mol/L, every hole 0.1ml.Set up normal cell contrast, virus control and positive drug matched group simultaneously.37 ℃ of cultivations, every day the observation of cell metamorphosis.Test is final observing time when changing with virus control hole Gestalt, and record CPE. presses the medium effective concentration (IC that the REED-MUENCH method is calculated C-3559
50). test repeats secondary, the results are shown in following table.
C-3559 anti-SARS virus IC
50
The experiment batch | The experiment date | Drug level (μ mol/L) | The CPE/ hole | Infective virus amount TCID 50 | IC50 (μmol/L) |
I | 2003.5.12- 2003.5.14 | 20.0 | ---- | 10 | 0.86 |
10.0 | ---- | ||||
5.0 | ---- | ||||
2.5 | ---- | ||||
1.3 | +++- | ||||
0.6 | 3+3+3+3+ | ||||
0.3 | 4+4+4+4+ | ||||
0 | 4+4+4+4+ | ||||
II | 2003.5.20- 2003.5.22 | 20.0 | ---- | 100 | 1.57 |
10.0 | ---- | ||||
5.0 | ---- | ||||
2.5 | +-++ | ||||
1.3 | 3+3+3+3+ | ||||
0.6 | 3+4+3+4+ | ||||
0.3 | 4+4+3+4+ | ||||
0 | 4+4+3+4+ | ||||
20.0 | ---- | 10 | 0.34 | ||
10.0 | ---- | ||||
5.0 | ---- | ||||
2.5 | ---- | ||||
1.3 | +--- | ||||
0.6 | +--- | ||||
0.3 | 2+2+2+2+ | ||||
0 | 4+4+3+3+ | ||||
Ribavirin | 400.0 | ++-+ | 100 | 52.0 (μg/ml) | |
200.0 | ++++ | ||||
100.0 | 2++++ | ||||
50.0 | 2+2+2+2+ | ||||
25.0 | 2+2+3+3+ | ||||
12.5 | 2+3+2+4+ |
Brief summary: C-3559 presses down the IC of sars coronavirus in the VERO-E6 cell
50Be 0.34~1.57 μ mol/L, the IC of positive control drug ribavirin
50Be 52.0 μ g/ml.
4. conclusion:
(1) C-3559 is changed to index with cellular morphology, the TD of C-3559 to cultivating 5 days in the toxicity of Vero-E6 cell: the C-3559 adding Vero-E6 cell
0Be 20 μ mol/L, TD
50Be 30 μ mol/L.
(2) C-3559 in the Vero-E6 cell to the inhibitory action of sars coronavirus: C-3559 suppresses the IC of sars coronavirus
50Be 0.34~1.57 μ mol/L; Test shows that C-3559 can obviously suppress sars coronavirus and duplicate; Average IC
50Be 0.96 μ mol/L.
(3) therapeutic index of C-3559 (TI) is 19~88.
(4) IC of positive control drug ribavirin
50Be 52.0 μ g/ml, TI>115.Annotate: IC
50The drug level that=inhibition 50% cytopathy or plaque form.
Therapeutic index=TD
50/ IC
50
Claims (1)
1. the application of geldanamycin in preparation treatment SARS (Severe Acute Respiratory Syndrome) SARS medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031465919A CN1179723C (en) | 2003-07-08 | 2003-07-08 | Application of geldanamycin in preparation of medicine for curing SARS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031465919A CN1179723C (en) | 2003-07-08 | 2003-07-08 | Application of geldanamycin in preparation of medicine for curing SARS |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1460474A CN1460474A (en) | 2003-12-10 |
CN1179723C true CN1179723C (en) | 2004-12-15 |
Family
ID=29591394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031465919A Expired - Fee Related CN1179723C (en) | 2003-07-08 | 2003-07-08 | Application of geldanamycin in preparation of medicine for curing SARS |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1179723C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102144971B (en) * | 2011-03-30 | 2012-10-03 | 天津红日药业股份有限公司 | Fasudil-containing oral spray or aerosol |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111135300A (en) * | 2020-01-09 | 2020-05-12 | 南京大学 | Application of protein inhibitor in preparation of medicine for relieving pneumonia caused by haze |
-
2003
- 2003-07-08 CN CNB031465919A patent/CN1179723C/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102144971B (en) * | 2011-03-30 | 2012-10-03 | 天津红日药业股份有限公司 | Fasudil-containing oral spray or aerosol |
Also Published As
Publication number | Publication date |
---|---|
CN1460474A (en) | 2003-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104940239B (en) | Cockroach extract and preparation method and application thereof | |
EP0374888A3 (en) | Sulfated tannins and theirs salts | |
CN106146603A (en) | A kind of preparation method of Cleistanone derivant | |
CN110354113B (en) | Borneol derivative antibacterial agent and preparation method and application thereof | |
CN109265504B (en) | 4-amino acid substituted pyrimidine nucleoside compound and pharmaceutical application thereof | |
CN1179723C (en) | Application of geldanamycin in preparation of medicine for curing SARS | |
CN111202739A (en) | Application of sophorolipid in preparing medicine for resisting propionibacterium acnes and biomembrane thereof | |
CN111888390B (en) | Application of Xiasangju extract in inhibiting human coronavirus | |
CN115381816A (en) | Application of VER50589 in preparing medicine for resisting enterovirus 71 | |
CN111939152B (en) | Application of ellagic acid metabolite Urolithin A in preparation of anti-enterovirus drugs | |
CN114748466A (en) | Application of Napyraclostrobin compound in preparation of porcine pseudorabies virus inhibitor | |
CN1680568A (en) | Microbiological coverting product of curcumenol, use and preparation thereof | |
CN112961783A (en) | Plant endophytic fungus and application thereof in preparation of spironolactone derivative | |
CN1895300A (en) | Kosam extract, its extraction and use | |
CN102070588A (en) | Alpha-pyrone compounds, and preparation method and application thereof | |
CN113797193B (en) | Application of trimethoxy quercetin in preparation of anti-coronavirus medicines | |
CN1843349A (en) | Use of lychee seed flavonoid and anthraquinone compound in preventing and treating respiratory syncytial virus infectious disease | |
CN112279841A (en) | Antiviral andrographolide derivative and preparation method thereof | |
CN114452273B (en) | Application of iodized hydrazide and iodized hydrazide polyacid derivative in preparation of CVB3 virus resistant drugs | |
CN112159395B (en) | 4-alanine substituted cytosine nucleoside compound and pharmaceutical application thereof | |
CN111346086B (en) | Application of compound in preparation of antiviral drug | |
CN108276363B (en) | Aspergillus glaucus secondary metabolite and application thereof in preparing antifungal drugs | |
CN103361276A (en) | Saccharopolyspora spinosa HBERC-25376, culturing method thereof as well as separation method and application of active substances thereof | |
CN110448623B (en) | Preparation method of banana leaf extract and application of banana leaf extract in resisting chikungunya virus | |
CN1245408C (en) | Use of Maituolaicin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041215 Termination date: 20120708 |